• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet asks court to force docs from Unilife in Chap 11 sale

June 22, 2017 By Fink Densford

Insulet, Unilife

A Delaware judge this week ordered formal submissions from both Unilife (NSDQ:UNIS) and Insulet (NSDQ:PODD) as the companies fought over Unilife’s Chapter 11 sale, with Insulet claiming Unilife is selectively refusing to supply appropriate information and restricting it’s ability to participate.

Insulet claims that Unilife has not provided it with enough data to make an informed bid on the assets, and has specifically targeted the company in its refusals, even after it signed a non disclosure agreement in May.

“Insulet submits that it is functionally impossible to value the Debtors’ intellectual property without knowing the pricing, development and licensing terms, and other key terms of the agreements between the Debtors and its customers, such as Amgen,” the company wrote in its letter.

Insulet went on to request that the court compel Unilife to “comply with the spirit and terms of the bidding procedures and open up the sale process so that all potential bidders, including outside third-parties such as Insulet, have a genuine ability to participate in the sale process.”

In response, Unilife argued that allowing Insulet access to sensitive information would hurt its dual-track process, which includes a possible reorganization and restructuring of the business.

In its letter to the court, Unilife argued that Insulet is a “competitor and the information it sinks is sensitive competitive information, the disclosure of which could damage the Debtors’ business and destroy value.”

Unilife goes on to accuse Insulet of “not participating in the sale process out of a legitimate desire to purchase the Debtor’s business assets, but rather (as is frequently the case) to appropriate proprietary information and trade secrets to gain a strategic advantage and potentially damage the Debtors’ sale or restructuring prospects.”

In the letter, Unilife said it had gone “to great lengths” to accommodate their requests for information, including access to an electronic data room, a tour of their York, Penn.-based facilities, a management presentation and redacted versions of customer contracts. “Insulet has requested and received more information than any other prospective bidder,” Unilife claims in its letter.

Unilife suggested that Insulet submit a conditional bid with an amount it’s willing to pay, subject to certain assumptions or conditions regarding information not provide, “or to simply walk away from the sale process,” according to its letter.

In May, Unilife won approval from the US Bankruptcy Court for the District of Delaware for its chapter 11 bid and plans for a sale, despite not having completed every step in the process.

Filed Under: Business/Financial News, Featured, Legal News Tagged With: Insulet, Unilife Corp.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS